Inovio Pharmaceuticals Inc (INO) Expected to Earn FY2022 Earnings of $0.20 Per Share

Share on StockTwits

Inovio Pharmaceuticals Inc (NASDAQ:INO) – Stock analysts at Piper Jaffray Companies cut their FY2022 earnings per share estimates for shares of Inovio Pharmaceuticals in a research report issued to clients and investors on Wednesday, February 20th. Piper Jaffray Companies analyst C. Raymond now forecasts that the biopharmaceutical company will post earnings of $0.20 per share for the year, down from their prior estimate of $0.23. Piper Jaffray Companies also issued estimates for Inovio Pharmaceuticals’ FY2023 earnings at $0.58 EPS.

A number of other analysts have also recently commented on the company. Maxim Group set a $8.00 price objective on Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday. BidaskClub lowered Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, February 14th. Zacks Investment Research raised Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a research note on Thursday, February 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Inovio Pharmaceuticals in a research note on Friday, January 25th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $9.65.

Inovio Pharmaceuticals stock opened at $3.75 on Thursday. The stock has a market cap of $351.83 million, a P/E ratio of -3.44 and a beta of 1.96. Inovio Pharmaceuticals has a 52 week low of $3.63 and a 52 week high of $6.30.

In other Inovio Pharmaceuticals news, CFO Peter Kies sold 10,001 shares of the firm’s stock in a transaction dated Thursday, November 29th. The stock was sold at an average price of $5.28, for a total value of $52,805.28. Following the sale, the chief financial officer now directly owns 72,089 shares of the company’s stock, valued at approximately $380,629.92. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 9.40% of the stock is currently owned by company insiders.

A number of large investors have recently modified their holdings of INO. Wasatch Advisors Inc. boosted its stake in Inovio Pharmaceuticals by 74.1% in the 3rd quarter. Wasatch Advisors Inc. now owns 4,767,879 shares of the biopharmaceutical company’s stock worth $26,509,000 after buying an additional 2,029,689 shares during the last quarter. ARK Investment Management LLC lifted its stake in shares of Inovio Pharmaceuticals by 60.5% in the 3rd quarter. ARK Investment Management LLC now owns 1,917,071 shares of the biopharmaceutical company’s stock valued at $10,659,000 after purchasing an additional 722,414 shares in the last quarter. D. E. Shaw & Co. Inc. lifted its stake in shares of Inovio Pharmaceuticals by 125.2% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,073,086 shares of the biopharmaceutical company’s stock valued at $4,292,000 after purchasing an additional 596,684 shares in the last quarter. Defender Capital LLC. acquired a new position in shares of Inovio Pharmaceuticals in the 4th quarter valued at about $2,324,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Inovio Pharmaceuticals by 446.4% in the 3rd quarter. Dimensional Fund Advisors LP now owns 520,426 shares of the biopharmaceutical company’s stock valued at $2,894,000 after purchasing an additional 425,188 shares in the last quarter. 35.36% of the stock is currently owned by hedge funds and other institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

Featured Story: What is the NASDAQ?

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.